查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600758

月經治療藥物市場：按類型、治療方法、分銷管道和最終用戶分類 - 全球預測 2025-2030

Dysmenorrhea Treatment Market by Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment (Medication, Surgery, Therapeutics), Distribution Channel, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年月經痛治療市場價值為71.6億美元，預計到2024年將達到78億美元，複合年成長率為8.98%，到2030年將達到130.9億美元。

月經藥物市場包括一系列旨在緩解月經痛的藥物、設備和替代療法，經痛困擾著世界上很大一部分女性人口。月經的高盛行率及其對生活品質、生產力和心理健康的影響推動了對這些治療的需求。應用範圍從非類固醇消炎劑(NSAID) 等非處方止痛藥到荷爾蒙療法以及經皮神經電刺激 (TENS) 和針灸等新型干涉措施。主要最終用戶包括醫院、診所和尋求家庭救濟的個人消費者。推動市場成長的是意識的提高、獲得醫療保健的機會的改善以及實現個人化醫療的生物技術的進步。人們對非侵入性替代醫學日益成長的興趣正在進一步擴大治療範圍。然而，傳統治療方法的副作用、低度開發地區缺乏認知以及監管障礙等挑戰構成了主要障礙。市場參與企業必須克服這些限制，同時透過對侵入性較小、更有效的解決方案進行創新研究來解決未滿足的需求，例如神經刺激和穿戴式科技的突破性應用。支持婦女健康的政府政策和增加研發投資帶來了龐大的商機。抓住這些機會的建議包括加強教育、關注服務不足的市場以及促進與醫療保健提供者的合作以提高產品的採用率和信任度。此外，強調透過自然療法和生物技術開發無副作用的治療方法也可能吸引消費者的興趣。對市場特徵的考慮表明，競爭格局正在隨著科學的進步而演變，消費者的偏好正在轉向整體健康方法，並且人們越來越重視結合藥品和技術進步的綜合解決方案。創新成熟的關鍵領域包括數位健康與即時監測的整合，以及探索符合最少干涉和負擔能力偏好的替代疼痛管理技術。

主要市場統計
基準年[2023] 71.6億美元
預測年份 [2024] 78億美元
預測年份 [2030] 130.9億美元
複合年成長率（%） 8.98%

市場動態：快速發展的月經藥物市場的關鍵市場洞察

供需的動態交互作用正在改變月經藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 月經的盛行率以及有效治療方案的需求
    • 提高對婦女生殖健康的認知以及政府擴大婦女醫療保健的努力
  • 市場限制因素
    • 月經藥物及器材產品召回相關問題
  • 市場機會
    • 月經治療進展及新藥出現
    • 穿戴式科技的採用和數位健康的普及
  • 市場挑戰
    • 月經管理的社會障礙與污名化

波特五力：駕馭月經藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對月經治療藥物市場的影響

外部宏觀環境因素對月經治療藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解月經治療藥物市場的競爭狀況

對月經治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 經痛藥市場廠商定位月經績效評估

FPNV定位矩陣是評估月經治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 月經的盛行率以及有效治療方法的必要性
      • 人們對婦女生殖健康的認知不斷提高，政府努力擴大婦女的醫療保健
    • 抑制因素
      • 月經藥品及醫療設備產品召回相關問題
    • 機會
      • 月經治療的進展和新藥的出現
      • 穿戴式科技的引入和數位健康的傳播
    • 任務
      • 關於月經治療的社會障礙與恥辱
  • 市場區隔分析
    • 類型：原發性經痛很常見，需要廣泛的止痛治療。
    • 治療：以子宮切除治療，永久緩解月經
    • 分銷管道：由於藥品和止痛貼片的便利性、保密性和有競爭力的價格，線上藥局越來越受到青睞。
    • 最終使用者：由於月經藥物易於取得且具有成本效益，因此擴大在家庭護理領域被採用。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章月經治療藥物市場：依類型

  • 原發性經痛
  • 次發性月經

第7章依治療方式分類的月經治療藥物市場

  • 藥物治療
    • 複方口服避孕藥
    • COX-2抑制劑
    • 非類固醇消炎劑
    • 非處方藥
    • 經皮三硝酸甘油酯
  • 外科手術
    • 子宮切除術
    • 子宮內避孕器
    • 腹腔鏡薦骨神經切除術
    • levonorgestrel子宮內避孕系統 (LN-IUS)
    • 骶前切除術
  • 治療藥物
    • 替代療法
    • 心理治療

第8章月經治療藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章月經治療藥物市場：依最終使用者分類

  • 居家護理
  • 醫院
  • 專科診所

第10章 北美和南美月經治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區月經治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的月經藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Mithra 申請在日本核准用於治療月經
    • Chime Biologics與Hope Medicine簽署生產協議，加速推出首個針對子宮內膜異位症和雄性禿的抗體醫藥品HMI-115
    • Mithra 從富士製藥接受250 萬歐元用於日本月經治療
    • 住友製藥和輝瑞公司在加拿大獲得加拿大衛生署核准MYFEMBREE
    • Gedeon Richter 和住友製藥獲得 CHMP 對子宮內膜異位症治療 RYEQO 的正面意見
    • 蒙特婁的新技術可以幫助緩解經期疼痛
    • Chugai Pharmaceutical 和 Bioformis 建立新的合作關係，專注於資料驅動的虛擬護理，治療與子宮內膜異位症相關的疼痛
    • Dare Bioscience開始治療原發性經痛的一期試驗
    • 健康科技Start-UpsOvira 正在幫助女性解決無需藥物即可緩解疼痛的重要問題。
    • 憑藉新的美麗靈感設計和擴展的健康產品組合，Cora 重新構想了經期護理，讓每個人都感覺更好。

公司名單

  • Abbott Laboratories
  • AA Pharma Inc.
  • Cora Life by LYV Life, Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited.
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Alfa Pharma GmbH
  • ASKA Pharmaceutical Co., Ltd.
  • Bayer AG
  • Lupin Pharmaceuticals, Inc.
  • Myoovi
  • Viatris Inc.
  • Myovant Sciences by Sumitovant Biopharma, Inc.
  • Sanofi SA
  • Cumberland Pharmaceuticals Inc.
  • GlaxoSmithKline PLC
  • Comforte Cream by PMS4PMS, LLC
  • Micro Labs Limited
  • LGM Pharma
  • Dr. Reddy's Laboratories Ltd.
  • Gedeon Richter Plc.
  • Alvogen, Inc.
  • Endo Pharmaceuticals Inc.
  • Perrigo Company PLC
  • Teva Pharmaceutical Industries Ltd.
  • Ovira
  • Ferring BV
  • F. Hoffmann-La Roche AG
  • Rael, Inc.
  • Novartis AG
  • Haleon PLC
  • Johnson & Johnson Services, Inc.
  • Hikma Pharmaceuticals PLC
  • Livia by iPulse Medical Ltd.
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-742BD517DA92

The Dysmenorrhea Treatment Market was valued at USD 7.16 billion in 2023, expected to reach USD 7.80 billion in 2024, and is projected to grow at a CAGR of 8.98%, to USD 13.09 billion by 2030.

The dysmenorrhea treatment market encompasses a range of pharmaceuticals, devices, and alternative therapies aimed at alleviating menstrual pain, which afflicts a substantial segment of the global female population. The necessity for these treatments is driven by the high prevalence of dysmenorrhea and its impact on quality of life, productivity, and mental health. Applications range from over-the-counter pain relievers, such as NSAIDs, to hormonal therapies and novel interventions like transcutaneous electrical nerve stimulation (TENS) and acupuncture. Key end-users include hospitals, clinics, and individual consumers seeking at-home relief options. Market growth is propelled by increasing awareness, improved healthcare access, and advances in biotechnology enabling personalized medicine. A growing interest in non-invasive and alternative medicine further expands the treatment scope. Nevertheless, challenges such as side effects of conventional therapies, lack of awareness in underdeveloped regions, and regulatory hurdles pose significant barriers. Market participants must navigate these limitations while addressing the unmet needs through innovative research into less invasive and more effective solutions, like breakthrough applications in neurostimulation and wearable technology. Governmental policies supporting women's health and rising investment in R&D present robust opportunities. Recommendations for capturing these opportunities include ramping up education efforts, focusing on under-served markets, and fostering collaborations with healthcare providers to expand product reach and endorse trust. Emphasizing the development of side-effect-free treatments through natural or biotechnological means could also capture consumer interest. Insights into the nature of the market reveal a competitive landscape that is evolving with scientific progress, consumer preferences shifting towards holistic health approaches, and a growing emphasis on integrated solutions combining medicinal and technological advancements. Key areas ripe for innovation include digital health integration with real-time monitoring and the exploration of alternative pain management techniques that align with preferences for minimal intervention and enhanced affordability.

KEY MARKET STATISTICS
Base Year [2023] USD 7.16 billion
Estimated Year [2024] USD 7.80 billion
Forecast Year [2030] USD 13.09 billion
CAGR (%) 8.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dysmenorrhea Treatment Market

The Dysmenorrhea Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of dysmenorrhea and the need for effective treatment options
    • Growing awareness about women's reproductive health and government initiatives to expand healthcare for women
  • Market Restraints
    • Issues associated with product recalls for dysmenorrhea drugs and devices
  • Market Opportunities
    • Advancements in therapy for dysmenorrhea and the emergence of novel drugs
    • Adoption of wearable technology and the proliferation of digital health
  • Market Challenges
    • Societal barriers and stigmatization regarding dysmenorrhea management

Porter's Five Forces: A Strategic Tool for Navigating the Dysmenorrhea Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dysmenorrhea Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dysmenorrhea Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dysmenorrhea Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dysmenorrhea Treatment Market

A detailed market share analysis in the Dysmenorrhea Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dysmenorrhea Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dysmenorrhea Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Dysmenorrhea Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AA Pharma Inc., Cora Life by LYV Life, Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited., Merck & Co., Inc., AbbVie Inc., Alfa Pharma GmbH, ASKA Pharmaceutical Co., Ltd., Bayer AG, Lupin Pharmaceuticals, Inc., Myoovi, Viatris Inc., Myovant Sciences by Sumitovant Biopharma, Inc., Sanofi S.A., Cumberland Pharmaceuticals Inc., GlaxoSmithKline PLC, Comforte Cream by PMS4PMS, LLC, Micro Labs Limited, LGM Pharma, Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc., Alvogen, Inc., Endo Pharmaceuticals Inc., Perrigo Company PLC, Teva Pharmaceutical Industries Ltd., Ovira, Ferring B.V., F. Hoffmann-La Roche AG, Rael, Inc., Novartis AG, Haleon PLC, Johnson & Johnson Services, Inc., Hikma Pharmaceuticals PLC, Livia by iPulse Medical Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Dysmenorrhea Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Primary Dysmenorrhea and Secondary Dysmenorrhea.
  • Based on Treatment, market is studied across Medication, Surgery, and Therapeutics. The Medication is further studied across Combined Oral Contraceptive Pills, Cox-2 Inhibitors, Non-Steroidal Anti-Inflammatory Drugs, Over-The-Counter Medications, and Transdermal Glyceryl Trinitrate. The Surgery is further studied across Hysterectomy, Intrauterine Device, Laparoscopic Uterosacral Nerve Ablation, Levonorgestrel Intrauterine System (LN-IUS), and Presacral Neurectomy. The Therapeutics is further studied across Alternative Therapies and Psychological Therapies.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of dysmenorrhea and the need for effective treatment options
      • 5.1.1.2. Growing awareness about women's reproductive health and government initiatives to expand healthcare for women
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with product recalls for dysmenorrhea drugs and devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in therapy for dysmenorrhea and the emergence of novel drugs
      • 5.1.3.2. Adoption of wearable technology and the proliferation of digital health
    • 5.1.4. Challenges
      • 5.1.4.1. Societal barriers and stigmatization regarding dysmenorrhea management
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Wide occurrence of primary dysmenorrhea and extensive need for pain relief management
    • 5.2.2. Treatment: Adoption of hysterectomy treatment to provide permanent relief from dysmenorrhea
    • 5.2.3. Distribution Channel: Growing preference for online pharmacies due to their convenience, discreteness, and competitive pricing of medications and pain relief patches
    • 5.2.4. End-Users: Increasing adoption of dysmenorrhea treatment in the homecare segment as it is easily accessible and cost-effective
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dysmenorrhea Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Primary Dysmenorrhea
  • 6.3. Secondary Dysmenorrhea

7. Dysmenorrhea Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Medication
    • 7.2.1. Combined Oral Contraceptive Pills
    • 7.2.2. Cox-2 Inhibitors
    • 7.2.3. Non-Steroidal Anti-Inflammatory Drugs
    • 7.2.4. Over-The-Counter Medications
    • 7.2.5. Transdermal Glyceryl Trinitrate
  • 7.3. Surgery
    • 7.3.1. Hysterectomy
    • 7.3.2. Intrauterine Device
    • 7.3.3. Laparoscopic Uterosacral Nerve Ablation
    • 7.3.4. Levonorgestrel Intrauterine System (LN-IUS)
    • 7.3.5. Presacral Neurectomy
  • 7.4. Therapeutics
    • 7.4.1. Alternative Therapies
    • 7.4.2. Psychological Therapies

8. Dysmenorrhea Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Dysmenorrhea Treatment Market, by End-Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Dysmenorrhea Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Dysmenorrhea Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Dysmenorrhea Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Mithra Submits Marketing Approval Application in Japan to Combat Dysmenorrhea
    • 13.3.2. Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
    • 13.3.3. Mithra to Receive EUR 2.5 Million from Fuji Pharma for Dysmenorrhea Treatment in Japan
    • 13.3.4. Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE
    • 13.3.5. Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO for Treatment of Endometriosis
    • 13.3.6. How New Tech from Montreal Could Help the Fight Against Period Cramps
    • 13.3.7. Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain
    • 13.3.8. Dare Bioscience Begins Phase I Trial of Primary Dysmenorrhea Therapy
    • 13.3.9. Healthtech Startup Ovira is Helping Women Tackle a Key Problem - Drug-Free Period Pain Relief
    • 13.3.10. Cora Reimagines Period Care with a New Beauty-Inspired Look and Expanded Wellness Portfolio to Make Comfort Accessible for Everyone

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AA Pharma Inc.
  • 3. Cora Life by LYV Life, Inc.
  • 4. Pfizer Inc.
  • 5. Takeda Pharmaceutical Company Limited.
  • 6. Merck & Co., Inc.
  • 7. AbbVie Inc.
  • 8. Alfa Pharma GmbH
  • 9. ASKA Pharmaceutical Co., Ltd.
  • 10. Bayer AG
  • 11. Lupin Pharmaceuticals, Inc.
  • 12. Myoovi
  • 13. Viatris Inc.
  • 14. Myovant Sciences by Sumitovant Biopharma, Inc.
  • 15. Sanofi S.A.
  • 16. Cumberland Pharmaceuticals Inc.
  • 17. GlaxoSmithKline PLC
  • 18. Comforte Cream by PMS4PMS, LLC
  • 19. Micro Labs Limited
  • 20. LGM Pharma
  • 21. Dr. Reddy's Laboratories Ltd.
  • 22. Gedeon Richter Plc.
  • 23. Alvogen, Inc.
  • 24. Endo Pharmaceuticals Inc.
  • 25. Perrigo Company PLC
  • 26. Teva Pharmaceutical Industries Ltd.
  • 27. Ovira
  • 28. Ferring B.V.
  • 29. F. Hoffmann-La Roche AG
  • 30. Rael, Inc.
  • 31. Novartis AG
  • 32. Haleon PLC
  • 33. Johnson & Johnson Services, Inc.
  • 34. Hikma Pharmaceuticals PLC
  • 35. Livia by iPulse Medical Ltd.
  • 36. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. DYSMENORRHEA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DYSMENORRHEA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DYSMENORRHEA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DYSMENORRHEA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE PILLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OVER-THE-COUNTER MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TRANSDERMAL GLYCERYL TRINITRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HYSTERECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INTRAUTERINE DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY LAPAROSCOPIC UTEROSACRAL NERVE ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY LEVONORGESTREL INTRAUTERINE SYSTEM (LN-IUS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRESACRAL NEURECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PSYCHOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 328. DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 329. DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023